A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

NCT05515432 | Completed Phase 1

• 2 other identifiers: 215932022-000858-28
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). The kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. High blood pressure makes it more likely that the CKD gets worse. The study treatment BAY3283142 is under development for treating CKD. It activates a protein called soluble guanylate cyclase (sGC) that generates cGMP - a molecule that relaxes blood vessels and is thought to have beneficial effects in CKD. The participants do not benefit from this study. However, the study will provide information on how to use BAY3283142 in subsequent studies in people with CKD. In previous studies, BAY3283142 was studied in participants with normal kidney function. As kidneys play a role in removal of drugs from the body, the degree of kidney function could influence the amount of BAY3283142 in the blood. Higher amounts may occur in people with reduced kidney function. Therefore, the main purpose of this study is to learn how the study treatment BAY3283142 moves into, through, and out of the body in participants with mild to severe reduction of kidney function compared to matched participants with normal kidney function. To answer this, the researchers will compare:

• the (average) total level of BAY3283142 in the blood (also called AUC).
• the (average) highest level of BAY3283142 in the blood (also called cmax) between the different groups. Participants will be in one of four groups based on how much their kidney function is reduced (mild, moderate, severe, end stage kidney disease) or in the control group. All participants will take a single dose of BAY3283142 as tablet by mouth. Each participant will be in the study for approximately 4 weeks including an in-house stay of 6 days (with 5 overnight stays). In addition, a screening visit to the study site before the in-house stay is planned. During the study, the study team will:
• check vital signs
• do physical examinations
• take blood and urine samples
• examine heart health using an electrocardiogram (ECG)
• ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

Conditions

Chronic Kidney Disease; Renal Impairment; Healthy Volunteers

Outcome Measures

Primary Outcomes (4)

• AUC of BAY3283142

  AUC(0-tlast) will be used as main parameters if AUC cannot be reliably determined in all participants

  up to 0 - 96 hours post-dose

• AUCu of BAY3283142

  AUC(0-tlast)u will be used as main parameters if AUC cannot be reliably determined in all participants

  up to 0 - 96 hours post-dose

• Cmax of BAY3283142

  up to 0 - 96 hours post-dose

• Cmax,u of BAY3283142

  up to 0 - 96 hours post-dose

Secondary Outcomes (1)

• Number of participants with treatment-emergent adverse events (TEAEs) after intake of BAY3283142

  up to 7 days post-dose

Study Arms (5)

Mildly impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥60 - <90

EXPERIMENTAL

Participants with renal impairment

Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

Moderately impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥30 - <60

EXPERIMENTAL

Participants with renal impairment

Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

Severely impaired renal funtion: eGFR (mL/min/1.73 m^2) <30

EXPERIMENTAL

Participants with renal impairment

Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

ESRD (end stage renal disease) on dialysis

EXPERIMENTAL

Participants with renal impairment

Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

Normal renal function (control group): eGFR (mL/min/1.73 m^2) ≥90

EXPERIMENTAL

Age-, weight-, and gender-matched participants with normal renal function as control group

Drug: Single oral dose of BAY3283142 IR (immediate release) tablet

Interventions

Single oral dose of BAY3283142 IR (immediate release) tablet DRUG

Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design

ESRD (end stage renal disease) on dialysis; Mildly impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥60 - <90; Moderately impaired renal funtion: eGFR (mL/min/1.73 m^2) ≥30 - <60; Normal renal function (control group): eGFR (mL/min/1.73 m^2) ≥90; Severely impaired renal funtion: eGFR (mL/min/1.73 m^2) <30

Eligibility Criteria

• Age: 18 Years - 82 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be 18 to 82 years of age inclusive, at the time of signing the informed consent.
• Normal kidney function or at different stages of renal impairment (mild to severe renal impairment, ESRD with hemodialysis or hemodiafiltration).
• Race: White (Note: Clinical Data Interchange Standards Consortium \[CDISC\] definition of White: Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White \[FDA\]).
• Body mass index (BMI) within the range 18.0 and 35.0 kg/m\^2 (both inclusive).
• Body weight equal or above 55 kg.
• Male or female participants; women have to be of non-childbearing potential as defined in Section 10.4.1 (e.g., postmenopausal for at least 1 year, women with bilateral salpingectomy, women with bilateral ovariectomy, and women with hysterectomy).
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
• Men must agree to use a condom in sexual intercourse with female partner of childbearing potential and not to act as sperm donor for 10 days after dosing.
• eGFR \<90 mL/min/1.73 m\^2 alculated by the CKD-EPI formula (eGFR must be repeated if screening period \>10 days before dosing) 21 to 2 days prior to dosing and patients with ESRD on hemodialysis or hemodiafiltration.
• Stable renal function (e.g., a serum creatinine value determined at least 3 months before the screening visit should not vary by more than 25% from the serum creatinine value determined at the screening visit).
• eGFR ≥90 mL/min/1.73 m\^2 calculated by the CKD-EPI formula (eGFR must be repeated if screening period \>10 days before dosing) 21 to 2 days prior to dosing.
• Needs to be within the required matching age, gender, and body weight range.

You may not qualify if:

• Women of childbearing potential, pregnant or lactating women.
• Medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator.
• Known or suspected liver disorders (including Morbus Gilbert/Meulengracht) and bile secretion/flow (cholestasis).
• Known hypersensitivity to the study drugs (active substances or excipients of the preparations).
• Known severe allergies (e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids), urticaria, or significant non-allergic drug reactions.
• Relevant acute diseases within the last 4 weeks prior to intake of study intervention.
• Febrile illness within 2 weeks before intake of study intervention.
• Known tendency for vasovagal reactions (e.g., after venipuncture) or clinically relevant history of syncope.
• History of gastrointestinal surgery, with the exception of appendectomy unless it had been performed within the previous 12 months before screening.
• Acute diarrhea or constipation within 14 days before intake of study intervention.
• Diagnosed malignancy within the past 5 years with exception of completely resected basal cell cancer of the skin (excision \>6 months before screening).
• Planned intervention or surgery during the study which might impact the study objectives.
• History of clinically relevant bleeding within the past 3 months.
• Thrombotic disorder.
• Use of systemic or topical medicines or substances which oppose the study objectives

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

CRS Clinical-Research-Services Kiel GmbH

Kiel, Schleswig-Holstein, 24105, Germany

Location

Related Links

• Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Renal Insufficiency

Interventions

Tablets

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Dosage Forms; Pharmaceutical Preparations

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2022
• First Posted: August 25, 2022
• Study Start: August 11, 2022
• Primary Completion: March 7, 2023
• Study Completion: June 6, 2023
• Last Updated: August 21, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)